ACADIA Pharmaceuticals Added to Russell 2000 Index

SAN DIEGO—(BUSINESS WIRE)—Jul. 1, 2013—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on innovative treatments that address unmet medical needs inneurological and related central nervous system disorders, todayannounced that it has been added to the Russell 2000 Index effectiveafter the close of market on Friday, June 28, 2013, as part of RussellInvestments’ annual index reconstitution. ACADIA also was added to theRussell 3000 and Russell Global Indexes.

The annual reconstitution of the Russell 3000 captures the 3,000 largestU.S. stocks as of the end of May, ranking them by total marketcapitalization. The largest 1,000 companies in this ranking make up theRussell 1000 and the next 2,000 companies comprise the Russell 2000. TheRussell 3000 also serves as the U.S. component to the Russell GlobalIndex. Russell indexes are widely used by investment managers andinstitutional investors for index funds and as benchmarks for passiveand active investment strategies. Approximately $4.1 trillion in assetsare benchmarked to the Russell indexes. For more information aboutRussell indexes, visit: http://www.russell.com/indexes/.

About Russell Investments

Russell Investments (Russell) is a global asset manager and one of onlya few firms that offers actively managed multi-asset portfolios andservices that include advice, investments and implementation. Russellstands with institutional investors, financial advisors and individualsworking with their advisors—using the firm’s core capabilities thatextend across capital market insights, manager research, portfolioconstruction, portfolio implementation and indexes to help each achievetheir desired investment outcomes.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatmentsthat address unmet medical needs in neurological and related centralnervous system disorders. ACADIA has a pipeline of product candidatesled by pimavanserin, which is in Phase III development as a potentialfirst-in-class treatment for Parkinson's disease psychosis. ACADIA alsohas clinical-stage programs for chronic pain and glaucoma incollaboration with Allergan, Inc. and two advanced preclinical programsdirected at Parkinson’s disease and other neurological disorders. Allproduct candidates are small molecules that emanate from discoveriesmade at ACADIA. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, either alone or with a partner,including clinical trials, and the benefits to be derived from ACADIA’sproduct candidates, in each case including pimavanserin. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA’s annual report on Form 10-K for the year ended December 31, 2012as well as ACADIA’s subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, ExecutiveVice President,
Chief Financial Officer and Chief BusinessOfficer
Lisa Barthelemy, Director of Investor Relations
(858)558-2871